® 40 "

: Simvastatin Teva ® 40 Mg. ?  »
|
-

PER OS

Tablets

Coronary Heart Disease : In patients with coronary heart disease and hypercholesterolemia Simvastatin-teva is indicated to: Reduce the risk of total mortality by reducing coronary death ;Reduce the risk of non-fatal myocardial infarction ;Reduce the risk for undergoing myocardial revascularization procedures. Reduce the risk of stroke and transient ischemic attacks (TIA). Hyperlipidemia: Simvastatin-teva is indicated as an adjunct to diet to reduce elevated TOTAL-C LDL-C Apo B and TG and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Frederickson Types IIa and IIb) Simvastatin-teva therefore lowers the LDL-C/HDL-C and the total-C/HDL-C ratios. Homozygous familial hypercholesterolemia: Simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol LDL-cholesterol and apolipoprotein B in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. Hypertriglyceridemia (Fredrickson type IV hyperlipidemia). Simvastatin-teva is indicated for the treatment of patients with hypertriglyceridemia ( Fredrickson type IV hyperlipidemia). Dysbetalipoproteinemia (Fredrickson type III hyperlipidemia): Simvastatin-teva is also indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia).

129 18 30737 00

Teva Pharmaceutical Works Private Limited Company, Hungary

10/2013 - 10/2023

.
, .
.
/
Simvastatin 40 MG
Blister pvc/pe/pvdc/al 10 x TABLETS 24
Blister pvc/pe/pvdc/al 30 x TABLETS 24
Blister pvc/pe/pvdc/al 60 x TABLETS 24
Blister pvc/pe/pvdc/al 100 x TABLETS 24

*

*

 

.

? !
 »
 
" !
 
370
-